Primary Rituximab and Maintenance
Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy
Sponsor: Australasian Leukaemia and Lymphoma Group
Listed as NCT00140582, this PHASE3 trial focuses on Follicular Lymphoma and remains completed. Sponsored by Australasian Leukaemia and Lymphoma Group, it has been updated 8 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Australasian Leukaemia and Lymphoma Group
- German Low Grade Lymphoma Study Group
- HOVON - Dutch Haemato-Oncology Association
- Institute of Cancer Research, United Kingdom
- Lymphoma Study Association
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Auckland, New Zealand , Bangkok, Thailand , Barcelona, Spain , Bogotá, Colombia , Bordeaux, France , Buenos Aires, Argentina , Créteil, France , Ghent, Belgium , Herlev, Denmark , Lille, France and 12 more locations